Home › Septic Shock › NCT06693726
Early Angiotensin II in the Emergency Department
RecruitingPhase 4
ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria 1. Age ≥18; and 2. Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and 3. Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and 4. Can provide written informed consent (or legally authorized representative). Exclusion Criteria 1. Acute coronary syndrome; 2. Cardiogenic shock; 3. Patients with a history of mesenteric ischemia; 4. Patients with a history of having an aortic dissection or abdominal aortic aneurysm; 5. Patients with an expected lifespan of \<12 hours; 6. Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells); 7. Active administration of two vasoactive agents before enrollment; and 8. Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.
About the study
This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
What is being tested
- Angiotensin II Infusion (drug)
Sponsor: Brett A Faine · Participants: 20 · Started: Apr 1, 2025
Contact the study team
- Brett Faine, PharmD · Phone: +1 319 356 2577
Official record on ClinicalTrials.gov — NCT06693726
Locations in the U.S.
| Iowa | University of Iowa Hospitals and Clinics, Iowa City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.